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Introduction: In the UK, the fasting plasma concentrations of a panel of gut hormones
(comprising vasoactive intestinal peptide (VIP), gastrin, pancreatic polypeptide (PP),
glucagon, somatostatin and chromogranin A) are measured to evaluate patients who
have or who (due to unexplained and compatible symptoms) are suspected of having
neuroendocrine tumors (NETs). False positive elevated hormone concentrations are
sometimes found.
Objective: To evaluate the frequency and implications of false positive fasting gut
hormone results.
Methods: Retrospective audit of fasting gut hormone profile results at a large UK
university teaching hospital over 12 months.
Results: Fasting gut hormone concentrations were measured in 231 patients during
2017. No NETs were found in the 88 patients who had this test performed only to
investigate symptoms. 31 false positive gastrin, 8 false positive chromogranin A, two false
positive glucagon, three false positive somatostatin, one false positive PP, and one false
positive VIP results were found. We extended the audit for glucagon and somatostatin for
an additional two years and found seven probable false-positive raised glucagon
concentrations and four probable false-positive elevated plasma somatostatin
concentrations in total.
Conclusions: False-positive elevations of plasma gastrin and chromogranin A were
common and causes such as proton pump inhibitor use or inadequate fasting accounted
for most cases. Elevated plasma concentrations of the other gut hormones were also
detected in patients who had no other evidence of NET. Other diagnoses (e.g. cirrhosisn.org December 2020 | Volume 11 | Article 6062641
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Frontiers in Endocrinology | www.frontiersiand medullary thyroid carcinoma for hypersomatostatinemia and type 2 diabetes mellitus,
pancreatitis, liver or renal impairment for hyperglucagonemia) may cause these false
positive results.Keywords: gut hormones, somatostatin, glucagon, neuroendocrine neoplasia, false positiveINTRODUCTION
Neuroendocrine tumors (NETs) comprise a diverse set of
neoplasms that can arise at various anatomical sites (1). NETs can
present with diverse symptoms and many cases are also detected
incidentally during investigations for unrelatedmedical conditions
(2). Although many NETs are non-functional (i.e. they do not
secrete hormones), a significant minority secrete hormones and
peptides resulting in classical functional syndromes of hormone
excess. With the exception of carcinoid syndrome, which is
most frequently associated with liver metastases from a primary
small bowel NET, most other functional NETs arise in the
foregut, especially the pancreas. Such tumors can secrete a
range of hormones (usually in isolation) such as insulin,
gastrin, somatostatin, glucagon or vasoactive intestinal peptide
(VIP) and excess secretion of these hormones may result in
classical syndromes (3). For example, gastrinomas result in
overproduction of gastric acid and Zollinger-Ellison syndrome,
somatostatinomas are classically associated with the triad of type 2
diabetes mellitus, cholelithiasis and diarrhea while glucagonomas
can cause the necrolytic migratory erythema skin rash, type 2
diabetes mellitus and weight loss (3, 4). Most pancreatic NETs
develop sporadically, but a minority are associated with genetically
inherited syndromes such as multiple endocrine neoplasia type 1
(MEN1), von Hippel Lindau syndrome or neurofibromatosis type
1 (3).
Patients who are suspected or confirmed as having a NET
usually undergo comprehensive biochemical and radiological
investigations to fully characterize the primary site and extent
of metastatic spread of their tumors (5, 6). The results of these
investigations influence the choice of treatment and also provide
prognostic information. One component of the diagnostic
evaluation of a patient with a possible NET is to perform a
biochemical assessment of its functional status (3). Most patients
also usually undergo cross-sectional and functional imaging
investigations (e.g. CT/MR scan, Octreoscan or 68Ga DOTA-
peptide PET/CT) and histological confirmation of the diagnosis
and tumor grading. The North American and European
neuroendocrine tumor societies (NANETS and ENETS) have
published guidance on the appropriate use of biochemical tests in
various scenarios, particularly the assessment of potential
functional pancreatic NETs. In many countries therefore,
clinicians request analysis of the concentrations of individual
gut hormones according to their clinical suspicion. However, the
situation in the UK is somewhat different, in that the vast
majority of hospitals send their samples to be analyzed at a
central supraregional accredited reference laboratory in London.
This laboratory performs a ‘fasting gut hormone profile’,
which measures the plasma concentration of the generaln.org 2NET biomarker, chromogranin A together with the plasma
concentrations of a number of enteroendocrine hormones
namely gastrin, somatostatin, glucagon, pancreatic polypeptide
(PP) and vasoactive intestinal peptide (VIP). Thus, even if the
clinician is only interested in measuring the concentration of an
individual hormone (e.g. gastrin in a patient with suspected
Zollinger-Ellison syndrome), the results of the whole gut
hormone profile are provided in the majority of cases. The
rationale may be that in certain conditions such as MEN1, the
concentrations of more than one gut hormone may be
simultaneously elevated. Other biochemical investigations such
as measurement of the plasma or 24 h urinary concentration of
5-HIAAmay also be undertaken, but these tests are distinct from
the ‘fasting gut hormone profile’ and are usually performed at
each base hospital rather than at the central facility.
In addition to its use in the assessment and monitoring of
patients who have confirmed NETs, the fasting gut hormone
profile is also used indiscriminately by some clinicians to
investigate whether unexplained symptoms such as persistent
diarrhea, facial flushing or ‘dizzy spells’ are caused by functional
NET syndromes. This is despite symptoms such as flushing
having a myriad of different NET and non-NET related causes
(7). The positive predictive value of the fasting gut hormone test
in this setting is consequentially very low. Therefore, it is not
uncommon for patients to be found to have elevated
concentrations of one or more gut hormones and to undergo
additional investigations to evaluate whether they have a NET.
Such investigations can be potentially invasive, expensive and
psychologically distressing and their results are frequently
unremarkable (i.e. the elevated gut hormone concentration is
eventually classified as a false-positive result).
We have recently observed an increasing volume of referrals to
the NET multidisciplinary team at Liverpool ENETS Centre of
Excellence to investigate patients who had been found to have
abnormal fasting gut hormone profiles, especially when these tests
had been ordered by non-NET specialist clinicians to investigate a
varietyofnon-specific symptoms.We therefore set out todetermine
the frequency of such false positive-fasting gut hormone test results
(i.e. in those patients who were subsequently found to have no
evidence of aNET) at our specialistNET center, the extent towhich
these biochemical results led to additional investigations and to
elucidate whether there were any potential explanations for the
abnormal test results.METHODS
We conducted a retrospective audit using electronic patient
records at the Royal Liverpool University Hospital, Liverpool,December 2020 | Volume 11 | Article 606264
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patients within Liverpool’s European Neuroendocrine Tumour
Society (ENETS) Centre of Excellence. Every patient who had a
fasting gut hormone test performed between 1st January 2017 and
31st December 2017 was identified from an electronic database.
Information was collected regarding patient demographics, clinical
indication for the test and diagnoses from histology, radiology and
biochemistry reports and electronic patient records. The project did
not require ethical approval, butwas registered and approved by the
hospital’s audit department.
We subsequently extended the audit to include the 3 year
period between August 2016 and August 2019 using the
same methodology specifically to evaluate all patients who
had elevated concentrations of glucagon or somatostatin.
We explored alternative potential causes for the elevated
concentrations of these hormones in those patients who did
not have a confirmed NET.
Fasting plasma gut hormone assays were analyzed
by radioimmunoassay at the Department of Molecular
Endocrinology, Hammersmith Hospital and at Charing Cross
Hospital, London. These radioimmunoassays were developed
and validated in the academic laboratory of Prof S.R. Bloom over
several decades and are regarded by many investigators as
the gold standard assays for these hormones. The methods
employed are described in (8, 9). Details of the individual
radioimmunoassays used and their performances can be found
in the following publications: Gastrin: primary antibody Gas 8
1:10 (10); Glucagon: primary antibody RCS5 1:50 (11);
Pancreatic polypeptide: primary antibody HPP/CCK5 1:50 (12,
13); VIP: primary antibody V9 1:100 (14, 15); Somatostatin:
primary antibody K2 1:10 (16, 17); Chromogranin A: SAS
radioimmunoassay (18, 19). The assays are performed in a
fully accredited national UK National Health Service reference
laboratory which is subject to stringent regular audit and quality
control measures. Results of gut hormones were deemed to be
abnormal if they met any of the following criteria: gastrin
>40pmol/L, glucagon >50 pmol/L, pancreatic polypeptide (PP)
>300 pmol/L, VIP >30 pmol/L, somatostatin >150 pmol/L, or
Chromogranin A >60 pmol/L.RESULTS
Cohort Characteristics
Fasting gut hormone profiles were measured in 231 patients [135
female (58%)], median age 63 years (range 18–92 years) during
2017. Four patients had repeated tests within the study
timeframe, therefore 235 test results were evaluated. Tests were
requested by a variety of clinicians, the most frequent requesting
specialties being gastroenterology (48%), general surgery (24%)
and endocrinology (18%).
Tests were performed with varying levels of pre-investigation
probability of having a NET: 61 (26%) patients had a previously
diagnosed NET and the test was performed for surveillance, seven
(3%) patients had MEN1 and underwent fasting gut hormone
testing for surveillance of this condition and 75 (32%) patientsFrontiers in Endocrinology | www.frontiersin.org 3were tested because of a strong radiological suspicion of a NET (e.g.
the presence of a hypervascular pancreatic tumor or hypervascular
liver metastases compatible with NET with no primary tumor site
identified) or histopathological detection of a NET on a biopsy or
surgical resection specimen. Of these 143 patients, 136 were
eventually confirmed to have a NET and a NET was excluded in
the other seven patients (most of whom were being investigated
because of a radiological abnormality). The majority of these NETs
(71%) arose in the foregut, as expected by the hormones that are
tested in the “fasting gut hormone profile” (50% pancreatic, 13%
gastric, and 8%duodenal). In a few patients, the test was performed
due to an unknown primary site and the commonest other primary
site was small bowel (21%). The remaining 88 (39%) patients
underwent fasting gut hormone testing on account of
unexplained symptoms for which the referring clinician
considered NET to be within the differential diagnosis; these
patients had a wide range of symptoms with diarrhea (33%) and
flushing (14%) being themost common. The vast majority of these
tests (88%) were requested by clinicians who were not core
members of the hospital’s NET multidisciplinary team. None of
these 88 patients was subsequently confirmed to have a NET,
although the extent of subsequent investigations was
highly variable.
Fasting Gut Hormone Results
Within the whole cohort of 231 patients, elevated gastrin
concentrations were detected in 75 patients, chromogranin A
in 35, glucagon in 13, somatostatin in five, PP in three, and VIP
in two patients. Some patients had multiple elevated plasma
hormone concentrations, the most frequent combination being
raised gastrin and chromogranin A (n=7).
We next assessed what proportion of those patients who had
elevated concentrations of each hormone eventually had a
confirmed NET diagnosis and found that 31/75 patients with
elevated gastrin, 8/35 elevated chromogranin A, 2/13 elevated
glucagon, 3/5 elevated somatostatin, 1/3 elevated PP, and 1/2
elevated VIP concentrations had no other biochemical or
radiological evidence to confirm the presence of a NET (Table
1). The anatomical sites of the primary NETs that were
associated with true positive elevated concentrations of each
hormone are also shown in Table 1.
Degree of Hormone Elevations in True
and False Positive Cases
We next investigated whether the extent to which positive gut
hormone results were elevated correlated with whether they
represented true positive or false positive findings. When we
analyzed all 35 patients who had elevated chromogranin A
concentrations, we found significantly higher median
concentrations in the 27 patients who had a NET (213pM) (i.e.
true positive cases) compared to the eight patients who had no
evidence of NET (77pM) (i.e. false positive cases) (p<0.01, Mann
Whitney U test). Only two patients who had no evidence of a
NET had chromogranin A levels that were elevated more than
two times the upper limit of normal. However, we did not find any
such correlations for the other gut hormones, although in manyDecember 2020 | Volume 11 | Article 606264
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permit meaningful statistical analysis. For gastrin, glucagon,
somatostatin, PP and VIP, the median concentrations of the
elevated hormones were not significantly different between those
patients who had true positive and false positive elevations of
these tests. In this cohort therefore, the degree to which the
concentrations of gut hormones other than chromogranin A were
elevated did not provide a reliable method to distinguish whether it
was likely to represent a true positive or false positive result.Extension of the Audit for an Additional
Two Years Found Additional Cases
of False Positive Hyperglucagonemia
and Hypersomatostatinemia
In many patients, the causes of the false positive elevations of gut
hormones were readily apparent. For example, false positive
elevated concentrations of gastrin and chromogranin A
frequently resulted from the use of acid suppressing medications
and we found that tests being performed under non-fasting
conditions accounted for most of the small number of false
positive elevated concentrations of both PP and VIP. We are
unfortunately not able to attribute a final cause for the
hypergastrinemia that was found in 31 patients who had no
evidence of NET, as many patients did not have OGD to assess
for the presence of atrophic gastritis and/or H. pylori infection.
However, 61% of these patients were taking a proton pump
inhibitor, a well-documented cause of hypergastrinemia, and that
is likely toprovide theunderlying explanation inmost of these cases.
However, our findings of false positive elevations of glucagon
and somatostatin were more surprising and the causes of such
abnormalities are generally less well appreciated. We therefore
extended our audit to include an additional two years to seeFrontiers in Endocrinology | www.frontiersin.org 4whether we could detect any additional patients at our hospital
who had evidence of false positive elevations of glucagon
or somatostatin.
The audit was therefore extended to cover the three year
period between August 2016 and August 2019. 641 fasting gut
hormone tests were performed during this time (including some
patients who had multiple tests). We found a total of 38 patients
who had elevated plasma concentrations of glucagon, seven of
whom had no confirmed evidence of NET and nine patients who
had elevated plasma concentrations of somatostatin, four of
whom had no confirmed evidence of NET (Tables 2 and 3).
Most of the patients who were found to have elevated plasma
glucagon concentrations, but who were not already known to
have a NET, had only marginally elevated levels (only one had a
concentration that was more than two times the upper limit
of normal) (Table 2). Many of these patients were therefore
not referred for comprehensive investigations to exclude
glucagonoma. Two of these patients also had elevated
chromogranin A results, but these were probably caused by co-
existing end stage renal failure. We unfortunately cannot
therefore definitively exclude the presence of small pancreatic
glucagonomas in all these cases, but that diagnosis is considered
to be unlikely in most cases. Most of the patients who had
elevated plasma somatostatin concentrations in the absence of a
confirmed NET did undergo reasonably extensive additional
investigations and these tests ruled out a diagnosis of
pancreatic NET with a high degree of probability in all cases.
30 of the remaining “true positive” 31 patients who had elevated
plasma glucagon concentrations had evidence of pancreatic NETs.
Four of these patients also had MEN1. The median concentration
was 80pM (range 51-1809pM) with 12 of the 30 patients having
concentrations more than two times the upper limit of normal, five
of whom had concentrations more than 10 times the upper limit ofTABLE 1 | Association of elevated fasting gut hormone parameters with the presence of neuroendocrine tumor (NET).
Total number
of elevated
tests
Number of true positive tests in
patients who had a confirmed
NET
Primary sites of NET in patients who had true
positive elevated concentrations of each
hormone
Number of false-positive tests (number
with concentrations > 2× upper limit of
normal)
Gastrin 75 44 18 pancreas
14 gastric
6 duodenal
4 small bowel
1 lung
1 unknown primary
31 (16)
Glucagon 13 11 10 pancreas
1 small bowel
2 (1)
Somatostatin 5 2 2 pancreas 3 (2)
Pancreatic
polypeptide
(PP)
3 1 1 small bowel 2 (1 non-fasting and spurious) (2)
Vasoactive
intestinal
peptide (VIP)
2 1 1 pancreas 1 (non-fasting and spurious) (1)
Chromogranin
A
35 27 13 small bowel
8 pancreas
2 gastric
1 duodenal
1 lung
2 unknown primary
8 (2)December 2020 | Volume 11 | Article 606264
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pM showed any of the classical symptoms associated with
glucagonoma. It is therefore likely that the majority of the patients
who had only marginally elevated glucagon concentrations had non-
functional pancreatic NETs that were not secreting sufficient
glucagon to result in clinical manifestations. One patient who had
raised plasma glucagon levels (71 pM) had a small bowel NET, so
this too may have been a false positive result. Nonetheless we have
classified all these 31 patients as having true positive elevations of
plasma glucagon. The five patients who had true positive elevated
plasma somatostatin concentrations all had pancreatic NETs, but
none of them had confirmed MEN1. In all five cases, the degree of
increase was less than 1.5 times the upper limit of normal (median
193 pM, range 161–221 pM) and none presented with symptoms
associated with the classical “somatostatinoma syndrome.” These are
therefore more likely to be non-functional pancreatic NETs with
minimal elevation of plasma somatostatin concentration and do not
appear to have been secreting sufficient somatostatin to cause
clinical manifestations.DISCUSSION
This study has two main conclusions. Firstly, none of the 88
patients who underwent fasting gut hormone testing to evaluate
whether their non-specific symptoms were due to a functionalFrontiers in Endocrinology | www.frontiersin.org 5NET syndrome was eventually confirmed to have a NET. This
suggests that the use of the fasting gut hormone blood test is
probably inappropriate in this clinical scenario. As functional
pancreatic NETs such as somatostatinomas, glucagonomas,
PPomas and VIPomas are very rare (estimated incidences 1 in
10–40 million individuals per year), such an investigation
strategy is also likely to result in some false positive test results.
These will mean that the patient undergoes additional
investigations, which are expensive, but may also provoke
anxiety and significant psychological distress for patients and
have cost and resource implications for the NHS.
The second main finding of our study was that 47 of 133
(35%) elevated fasting gut hormone test results at our hospital in
2017 occurred in patients in whom there was no other evidence
of a NET. The most frequently elevated hormones (39 of these 47
cases) were gastrin and chromogranin A, but only 18 of the 39
patients who had false positive elevations of either of these
hormones showed an increase of more than two times the
upper limit of normal. The causes of false positive elevations of
gastrin and chromogranin A have previously been well
documented. Hypergastrinemia commonly results from
hypochlorhydria as a result of gastric pathology (autoimmune
or H. pylori associated atrophic gastritis), surgery (vagotomy) or
medication (proton pump inhibitor or H2 receptor antagonist use),
but can also be associated with other conditions includingH. pylori
infection per se, renal failure and retained gastric antrum afterTABLE 3 | Clinical details of patients with raised plasma somatostatin concentrations.
Patient
number
Gender Age
(years)
Plasma somatostatin (pM)
(N<150pM)
Indication for test Comorbidities Additional tests which showed
no evidence of NET
1 Male 43 156 Flushing, family history
of NET
Alcoholic liver disease CT, CgA, urinary 5-HIAA,
colonoscopy, OGD
2 Female 73 197 and 473 Non-healing peptic
ulcer
Liver transplant CgA, CT, OGD
3 Female 65 348 and 407 Diarrhea Bile acid diarrhea, breast cancer CgA, CT, 68Ga-DOTANOC PET/
CT, OGD, colonoscopy
4 Female 48 175 Vomiting Parenteral nutrition for recurrent
vomiting
CgA, CT, OGDDecember 2CT, computerized tomography scan; OGD, esophagogastroduodenoscopy; CgA, chromogranin A.TABLE 2 | Clinical details of patients with raised plasma glucagon concentrations.
Patient
number
Gender Age
(years)
Plasma glucagon (pM)
(N<50pM)
Indication for
test
Comorbidities Additional tests which showed
no evidence of NET
1 Male 73 56 Diarrhea Refractory coeliac disease, diffuse large B
cell lymphoma
CT, MR
2 Male 65 68 Diarrhea C. difficile colitis
End stage renal failure
CT (CgA elevated but attributed
to CKD)
3 Female 39 70 Diarrhea Type 2 diabetes, obesity, Nonalcoholic fatty
liver disease
CgA, US pancreas
4 Male 59 77,74 Diarrhea Type 2 diabetes, end stage renal failure,
C. difficile colitis
No imaging, CgA elevated but
attributed to CKD
5 Female 63 53 Sweats High output ileostomy following
panproctocolectomy
CT, CgA
6 Female 66 379, 241, 456 Diarrhea Ulcerative colitis, type 2 diabetes, chronic
pancreatitis
CT, MR, CgA, EUS, octreoscan
7 Female 69 62 Flushing Small bowel intussusception CgA, repeat glucagon 8pM, CT,
capsule enteroscopyCT, computerised tomography scan; MR, magnetic resonance scan; US, ultrasound scan; EUS, endoscopic ultrasound scan; CgA, chromogranin A; CKD, chronic kidney disease.020 | Volume 11 | Article 606264
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may be required to evaluate the cause of hypergastrinemia and to
assess for the presence of type I gastric neuroendocrine tumors in
any patients who have autoimmune atrophic gastritis. Elevated
circulating concentrations of chromogranin A can be found in
renal and hepatic impairment, chronic atrophic gastritis, proton
pump inhibitor use and inflammatory bowel disease (4).
Although rare, we also found potential false positive
elevations of some of the other gut hormones within our
cohort. False positive elevations of PP and VIP were extremely
rare and two of the three identified cases were spurious as a result
of the test being performed in the non-fasting state. However, we
also detected five patients in whom hyperglucagonemia and
hypersomatostatinemia did not appear to be associated with a
NET. We therefore extended our audit to search for additional
potential cases of false positive hyperglucagonemia and
hypersomatostatinemia over a longer three year audit period.
In total, we found four cases of probable false positive
hypersomatostatinemia (two of whom had somatostatin
concentrations more than two times the upper limit of normal
on at least one occasion) and seven cases of probable false
positive hyperglucagonemia (only one of whom had a glucagon
concentration more than two times the upper limit of normal).
Somatostatinomas are classically associated with a clinical triad
of diabetes mellitus, cholelithiasis and diarrhea, collectively termed
“somatostatinoma syndrome.” However most patients only have
partial manifestation of this triad (21). Somatostatinomas are very
rare (incidence approximately 1 in 40 million persons per year)
and approximately 45% are thought to arise in patients with
MEN1 (3). Patients with glucagonoma can present with necrolytic
migratory erythema (67%–90%), glucose intolerance (38%–87%)
and weight loss (66%–96%) (3). This tumor is also very rare
(approximately 1 in 20 million persons per year) and up to 20%
cases are thought to be associated with MEN1 (3).
Several studies have suggested that elevated circulating
concentrations of somatostatin can be found in patients who
have cirrhosis (22–26) or medullary carcinoma of the thyroid
(27–29). A single study also described elevated concentrations in
patients with hypothyroidism (30). There is also some evidence
to suggest that circulating somatostatin concentrations can be
increased in diabetes mellitus (31, 32) ulcerative colitis (33) and
vascular dementia (34). Studies have also confirmed that elevated
somatostatin concentrations are not associated with a range of
other conditions including autosomal dominant polycystic
kidney disease (35), chronic gastritis (36), biliary stone disease
(37), acromegaly (38), obesity (39, 40), chronic pancreatitis (41)
and irritable bowel syndrome (42). The published literature has
also suggested that circulating somatostatin concentrations tend
to increase with age (43, 44), but other physiological variables
such as gender and ethnicity do not seem to have a major
influence on this parameter (although there appear to have been
few studies that have systematically addressed this).
Liver cirrhosis andmedullary carcinomaof the thyroid therefore
appear to be the twomain conditions for which several studies have
reported an association with elevated fasting plasma somatostatin
concentrations. We note that two of the four patients in whom weFrontiers in Endocrinology | www.frontiersin.org 6identified false positive elevated somatostatin concentrations had
current or previous severe chronic liver disease (Table 2).
Circulating calcitonin or carcinoembryonic antigen (CEA)
concentrations were not measured in any of our patients, so we
cannot definitively exclude a diagnosis of medullary carcinoma of
the thyroid in the other two patients. However, none of the patients
have developed other signs of this disease during at least two years
follow up.
We found little evidence to suggest that physiological variants
such as age, gender and ethnicity have a significant effect upon
circulating glucagon concentrations (45). We did however identify
documented associations between elevated circulating glucagon
concentrations and a range of medical conditions. These include
diabetes mellitus (46–48) [including gestational diabetes (49)],
acute and chronic pancreatitis (50, 51), chronic kidney disease
(including that associatedwith type 2diabetesmellitus) (52, 53) and
liver cirrhosis (54–56). Small studies have also suggested potential
associations with hyperthyroidism (57) and the second trimester of
pregnancy (57), although these findings have not yet been
independently verified to the best of our knowledge.
There is therefore reasonable quality data frommore than one
independent study to suggest that diabetes mellitus, pancreatitis,
chronic kidney disease and cirrhosis may be potential reasons for
elevated circulating glucagon levels in the absence of a
glucagonoma. Of the seven patients that we identified who had
potential false positive fasting plasma glucagon concentrations,
three had diabetes mellitus, two had end stage renal failure and
one had chronic pancreatitis (Table 3). Plausible explanations
for hyperglucagonemia were therefore found in four of these
seven patients, and the remaining three patients all had fasting
glucagon concentrations (56, 53, 62 pM) that were only
minimally above the upper limit of normal for the assay (50pM).
One limitation of our study is that not all patients who had
abnormal results were referred to the NET multidisciplinary team
for full assessment. Thus, not all patients had comprehensive
investigations such as 68Ga DOTA-peptide PET/CT scans or
endoscopic ultrasound scans to exclude very small pancreatic or
duodenal NETs. However only two of the eleven patients that we
identified as having probable false positive elevated glucagon or
somatostatin concentrations did not have at least a CT scan,
and all patients who had hypersomatostatinemia underwent
esophagogastroduodenoscopy, so it is unlikely that many occult
NETs have been missed in this cohort. A further limitation is that
several patients did not undergo repeat testing (particularly after
advice about strict adherence to fasting) to exclude spurious results.
In conclusion, this study suggests that the fasting gut hormone
test is probably used inappropriately by some clinicians when it is
ordered to investigate whether symptomatic patients have rare
functional NET syndromes. When this panel of tests is performed
in isolation, it also appears to frequently generate results that are
potentially unhelpful and difficult to interpret. We therefore
recommend that elevations of gut hormone concentrations in
patients who are not already known to have a NET should
initially be confirmed by repeating the test and making sure
that the patient has been adequately fasted before any further
investigations are undertaken. Persistently elevated results,December 2020 | Volume 11 | Article 606264
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normal usually require further investigations (e.g. radiological
imaging) to evaluate for the presence of a NET. Clinicians who
order the fasting gut hormone test should also be aware that a
number of other medical conditions (e.g. liver and renal
impairment) or drugs (especially proton pump inhibitors
causing hypergastrinemia) can potentially cause elevated
concentrations of the various components of the gut hormone
profile. The presence of such conditions may influence whether
additional potentially expensive or invasive investigations should
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